Idiopathic pulmonary fibrosis: Difference between revisions

Content deleted Content added
→‎Signs and symptoms: minor ce updated ref
m Added short description
Tags: Mobile edit Mobile app edit iOS app edit App description change
 
(3 intermediate revisions by 3 users not shown)
Line 1:
{{Short description|Scarring of the lungs for no known reason}}
{{Use dmy dates|date=August 2022}}
{{Infobox medical condition (new)
Line 63 ⟶ 64:
IPF is believed to be the result of an aberrant wound healing process including/involving abnormal and excessive deposition of [[collagen]] (fibrosis) in the [[pulmonary interstitium]] with minimal associated [[inflammation]].<ref name=HarariCaminati>{{cite journal |vauthors=Harari S, Caminati A | title = IPF: new insight on pathogenesis and treatment | journal = Allergy| volume = 65 | issue = 5 | pages = 537–553 | year = 2010 | pmid = 20121758 | doi = 10.1111/j.1398-9995.2009.02305.x| s2cid = 21633787 | doi-access = free }}</ref> [[Cellular senescence]] is suspected to be a central contributing cause, a belief which is supported by benefits seen in patients given [[senolytic]] therapy.<ref name="pmid30616998">{{cite journal | vauthors = Justice JN, Nambiar AM, Tchkonia T, Kirkland JL | title = Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study | journal = [[EBioMedicine]] | volume = 40 | pages = 554–563 | date=2019 | url= | doi = 10.1016/j.ebiom.2018.12.052 | pmc=6412088 | pmid = 30616998}}</ref><ref name="pmid31451866">{{cite journal | vauthors = Palmer AK, Gustafson B, Kirkland JL, Smith U | title = Cellular senescence: at the nexus between ageing and diabetes | journal = [[Diabetologia]] | volume = 62 | issue=10 | pages = 1835–1841 | date=2019 | url= | doi = 10.1007/s00125-019-4934-x | pmc=6731336 | pmid = 31451866}}</ref><ref name="pmid32686219">{{cite journal | vauthors = Kirkland JL, Tchkonia T| title = Senolytic Drugs: From Discovery to Translation | journal = [[Journal of Internal Medicine]] | date=2020 | volume = 288 | issue = 5 | pages = 518–536 | doi = 10.1111/joim.13141 | pmid = 32686219| pmc = 7405395 | doi-access = free }}</ref>
 
It is hypothesized that the initial or repetitive injury in IPF occurs to the lung cells, called alveolar epithelial cells (AECs[[pneumocyte]]s), pneumocytes)the [[Type I cells|type I]] and [[type II cells]], which line the majority of the alveolar surface.<ref name=LoomisFlaherty>{{cite journal | vauthors = Loomis-King H, Flaherty KR, Moore BB | title = Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis | journal = Current Opinion in Pharmacology | volume = 13 | issue = 3 | pages = 377–385 | date = June 2013 | pmid = 23602652 | pmc = 3686907 | doi = 10.1016/j.coph.2013.03.015 }}</ref> When type I AECscells are damaged or lost, it is thought that type II AECscells undergo proliferation to cover the exposed [[basement membrane]]s. In normal repair, the hyperplastic type II AECscells die and the remaining cells spread and undergo a differentiation process to become type I AECscells. Under pathologic conditions and in the presence of [[transforming growth factor beta]] (TGF-β), [[fibroblasts]] accumulate in these areas of damage and differentiate into [[myofibroblasts]] that secrete collagen and other proteins.<ref name=LoomisFlaherty /> In the current classification of the pathogenesis of IPF, it is believed that it occurs by way of the formation of a UIP (usual interstitial pneumonia) lesion, which then undergoes the aforementioned pathological condition characteristic of IPF.<ref>{{cite journal | vauthors = Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SN, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC | display-authors = 6 | title = Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline | journal = American Journal of Respiratory and Critical Care Medicine | volume = 198 | issue = 5 | pages = e44–e68 | date = September 2018 | pmid = 30168753 | doi = 10.1164/rccm.201807-1255ST | s2cid = 52130702 }}</ref> Other proposed repeated injury mechanisms indicate that IPF may result not just from a UIP lesion, but also from NSIP and DAD (nonspecific interstitial pneumonia and diffuse alveolar damage) lesions,<ref name=":0">{{cite journal | vauthors = Maher TM, Wells AU, Laurent GJ | title = Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? | journal = The European Respiratory Journal | volume = 30 | issue = 5 | pages = 835–839 | date = November 2007 | pmid = 17978154 | doi = 10.1183/09031936.00069307 | s2cid = 17026757 | doi-access = free }}</ref> or a combination of several.
 
In the past, it was thought that [[inflammation]] was the first event in initiating lung tissue scarring. Later findings showed that the development of fibroblastic foci precedes the accumulation of inflammatory cells and the consequent deposition of collagen.<ref name="PardoSelman">{{cite journal |vauthors=Pardo A, Selman M | title = Idiopathic pulmonary fibrosis: new insights in its pathogenesis | journal = The International Journal of Biochemistry & Cell Biology| volume = 34 | issue = 12 | pages = 1534–1538 | year = 2002 | pmid = 12379275| doi = 10.1016/s1357-2725(02)00091-2}}</ref> This pathogenetic model is indirectly supported by the clinical features of IPF, including an insidious onset over several years, relatively infrequent acute exacerbations, and failure to respond to [[immunosuppressive therapy]].<ref name="HarariCaminati" /><ref name="SelmanKing">{{cite journal |vauthors=Selman M, King TE, Pardo A | title = Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy | journal = Annals of Internal Medicine| volume = 134 | issue = 2 | pages = 136–151 | year = 2001 | pmid = 11177318 | doi = 10.7326/0003-4819-134-2-200101160-00015| s2cid = 10955241 }}</ref> However, it is the belief of some researchers that the disease is a multi-mechanistic one, wherein the trigger for the disease may stem from abnormalities in any number of wound healing pathways, including the inflammatory response.<ref name=":0" /> Such abnormalities could occur in any number of the nine implicated pathways (clotting cascade, antioxidant pathways, apoptosis, inflammatory cytokines, angiogenesis and vascular remodelling, growth factors, surfactant and matrix regulatory factors),<ref name=":0" /> and that through further investigation into all nine, novel therapies and approaches could be proposed on a unique or case-by-case basis should attempts at treating or circumventing complications in any one pathway prove unsuccessful. A number of therapies that target fibroblast activation or the synthesis of extracellular matrix are currently in early testing or are being considered for development.{{citation needed|date=November 2020}}